Market Overview

Why Bristol-Myers Squibb's Stock is Trading Higher Today

Why Bristol-Myers Squibb's Stock is Trading Higher Today

Bristol-Myers Squibb Company (NYSE: BMY) shares are trading higher after the company announced the FDA has approved ZEPOSIA, its new oral treatment for relapsing forms of multiple sclerosis.

"With the FDA approval of ZEPOSIA, appropriate patients with relapsing forms of multiple sclerosis will have another oral treatment option with meaningful efficacy to help address the disease's hallmark relapses and brain lesions," said Samit Hirawat, M.D., chief medical officer at Bristol Myers Squibb.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders.

Bristol-Myers Squibb's shares were trading up 4.9% at $51.77 on Tuesday. The stock has a 52-week high of $68.34 and a 52-week low of $42.48.


Related Articles (BMY)

View Comments and Join the Discussion!

Posted-In: why it's movingNews FDA Movers Trading Ideas

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at